We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 523

Supreme Court to consider section 8 damage quantification

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 31 2014

The Supreme Court of Canada announced yesterday that it has granted leave to appeal the decision of the Federal Court of Appeal in a proceeding

Federal court prohibits the approval of a generic prodrug CELLCEPT (mycophenolate mofetil)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 26 2011

On July 13, 2011, the Federal Court allowed an application by Hoffman La-Roche Limited (“Roche”), pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. (“Apotex”) in respect of its generic version of the drug mycophenolate mofetil (“MMF”) until after the expiry of Canadian Patent No. 1,333,285 (the “285 Patent”

Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada

  • Bereskin & Parr LLP
  • -
  • Canada, Global
  • -
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the

Pharma in brief - Canada: Federal Court refuses stand-alone application to amend patent disclosure

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 28 2013

In this case, the Federal Court dealt with a sui generis application by the Applicant, F. Hoffmann-La Roche AG, based on ss 53(2) of the Patent Act

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

Canada-EU free trade deal: intellectual property issues for the pharmaceutical industry

  • Dentons
  • -
  • Canada, European Union
  • -
  • October 24 2013

Canada and the European Union (the "EU") have signed a tentative deal to open markets and drop nearly all import taxes on everything from food to

Federal Court dismisses application for a prohibition order in respect of PATADAY eye drop solution

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 18 2014

This case concerns a proposed generic version of the brand name drug PATADAY, an eye drop solution used to treat allergic and inflammatory eye

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Competition Bureau sets out preliminary views on patent agreement settlement enforcement

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • October 27 2014

On September 23, 2014, John Pecman, the Commissioner of Competition, delivered the keynote address at the George Mason University Pharma Conference

Application for leave to appeal granted - 30 October 2014

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 30 2014

On appeal from the judgment of the Federal Court of Appeal pronounced March 14, 2014. The applicants (collectively, “Sanofi”) are the pat